Cullin3 E3 ubiquitin ligase ubiquitinates a wide range of substrates through substrate-specific adaptors Bric-a-brac, Tramtrack, and Broad complex (BTB) domain proteins. These E3 ubiquitin ligase complexes are involved in diverse cellular functions. Our recent study demonstrated that decreased Cullin3 expression induces glioma initiation and correlates with poor prognosis of patients with malignant glioma. However, the substrate recognition mechanism associated with tumorigenesis is not completely understood. Through yeast two-hybrid screening, we identified potassium channel tetramerization domain-containing 2 (KCTD2) as a BTB domain protein that binds to Cullin3. The interaction of Cullin3 and KCTD2 was verified using immunoprecipitation and immunofluorescence. Of interest, KCTD2 expression was markedly decreased in patient-derived glioma stem cells (GSCs) compared with non-stem glioma cells. Depletion of KCTD2 using a KCTD2-specific short-hairpin RNA in U87MG glioma cells and primary Ink4a/Arf-deficient murine astrocytes markedly increased self-renewal activity in addition with an increased expression of stem cell markers, and mouse in vivo intracranial tumor growth. As an underlying mechanism for these KCTD2-mediated phenotypic changes, we demonstrated that KCTD2 interacts with c-Myc, which is a key stem cell factor, and causes c-Myc protein degradation by ubiquitination. As a result, KCTD2 depletion acquires GSC features and affects aerobic glycolysis via expression changes in glycolysis-associated genes through c-Myc protein regulation. Of clinical significance was our finding that patients having a profile of KCTD2 mRNA-low and c-Myc gene signature-high, but not KCTD2 mRNA-low and c-Myc mRNA-high, are strongly associated with poor prognosis. This study describes a novel regulatory mode of c-Myc protein in malignant gliomas and provides a potential framework for glioma therapy by targeting c-Myc function. Cell Death and Differentiation (2017) 24, 649-659; doi:10.1038/cdd.2016.151; published online 6 January 2017
The polyubiquitination and subsequent degradation of cellular proteins in proteasomes have a key role in many biological processes. In fact, dysregulation of the protein degradation system contributes to many cancers. 1 The ubiquitinationdependent protein degradation system is a 3-step process. Ubiquitin is activated by an E1 ubiquitin-activating enzyme. The activated ubiquitin is transferred by an E2 ubiquitinconjugating enzyme to the targeted protein, where it binds to lysine residues of the substrate by E3 ubiquitin ligase. E3 ubiquitin ligase complexes are classified into two families according to their domain: homologous to the E6-AP carboxyl terminus (HECT) domain ligases or really interesting new gene (RING) finger domain ligases. 2 The Cullin protein serves as a scaffold to connect two functional modules of E3 ubiquitin ligase, the catalytic RING-finger protein and the substrate-binding molecule. Cullin-RING ubiquitin ligases are the largest E3 ligase family in eukaryotes.
Cullin3, one of the RING-finger E3 ubiquitin ligase complexes, has an essential role in embryo development, cancer progression, and many other diseases. 3 Substrate specificity of Cullin3 is determined by substrate-specific adaptors that contain the Bric-a-brac, Tramtrack, and Broad complex (BTB) domain. There are nearly 200 BTB domain proteins in humans; however, not all BTB domain proteins interact with Cullin3. 4, 5 Polyubiquitination and subsequent protein degradation have fundamental roles in many physiological and pathological processes including tumorigenesis. Malignant gliomas including glioblastoma (GBM, WHO grade IV) are the most aggressive form of brain tumors. Despite considerable progress in diagnosis, surgery, and treatment over the past several decades, the median survival time of patients with GBM is o14 months following diagnosis. 6 Glioma stem cells (GSCs) are a sub-population of GBMs and are capable of tumor initiation, progression, and recurrence following therapy. 7, 8 Our recent study found that Cullin3 exerts a tumor-suppressor function in gliomagenesis by inhibiting the WNT and Sonic hedgehog (SHH) signaling pathways through degradation of disheveled segment polarity protein 2 (DVL2) and GLI family zinc-finger protein 2 (GLI2), respectively. c-Myc is a transcription factor that has a central role in various cellular processes involving cell proliferation, glycolytic metabolism, differentiation, and apoptosis. 10 c-Myc expression and function are tightly regulated in normal cells, whereas dysregulation of c-Myc expression has been implicated in the genesis of most human cancers. 11 Moreover, overexpression of c-Myc has an important role in gliomagenesis and its progression by generating GSCs. 12 However, the precise regulatory mechanism of c-Myc expression remains largely undetermined in malignant gliomas.
In this study, we found that potassium channel tetramerization domain-containing 2 (KCTD2) is an adaptor for the Cullin3 E3 ubiquitin ligase and that it degrades c-Myc through polyubiquitination. When KCTD2 expression was depleted in glioma cells and immortalized murine astrocytes, we found that these cells acquired GSC-like properties through increases in c-Myc protein. This regulatory mechanism of c-Myc expression by Cullin3-KCTD2 may provide an alternative therapeutic strategy in targeting GSCs for malignant glioma regression.
Results
Identification of KCTD2 as an adaptor of Cullin3 E3 ubiquitin ligase. Recently, our group found that suppression of Cullin3 E3 ubiquitin ligase activates GSC proliferation, selfrenewal, and tumorigenicity. 9 To further understand the molecular mechanisms governing substrate recognition of Cullin3, we performed yeast two-hybrid (Y2H) screening to identify adaptor proteins that interact with Cullin3. A human fetal brain cDNA library was screened using full-length Cullin3 as bait. We identified six BTB domain-containing proteins ( Figure 1a ). As decreased Cullin3 promotes tumorigenesis by activating GSC properties, we hypothesized that adaptor proteins expressed at low levels in GSCs compared with non-stem glioma cells (hereafter, referred to as glioma cells) may be involved in Cullin3-driven GSC genesis. Therefore, we first compared expression levels of these adaptors in four normal astrocytes, five glioma cells, and seven GSCs using transcriptome microarray data. 13 We found that only KCTD2 mRNA levels were lower in glioma cells and GSCs compared with normal astrocytes, and significantly lower in GSCs relative to glioma cells (Figure 1b) . Quantitative reverse transcription polymerase chain reaction (qRT-PCR) analysis showed that expression levels of KCTD2 mRNA were markedly lower in all 10 GSCs tested compared with 4 out of 6 glioma cells (Figure 1c) . Although mass spectrometry previously suggested KCTD2 was a putative adaptor for Cullin3, 14 there was no evidence of a direct interaction. In this study, we focused on determining whether KCTD2 is a putative tumor suppressor. We first confirmed direct interaction of KCTD2 with Cullin3. One-onone Y2H analysis was performed using selective growth medium. Yeast can colonize media lacking leucine and tryptophan through vector transformation. However, if Cullin3 interacts with KCTD2, colonies can form on media deficient in four amino acids. As further support, their binding ability was confirmed using β-galactosidase (β-gal) staining (Figure 1d ).
In addition, a co-immunoprecipitation assay demonstrated an interaction between KCTD2 and Cullin3 in HEK 293 T cells (Figure 1e ). Colocalization of KCTD2 and Cullin3 was examined using immunofluorescence. The results showed that both KCTD2 and Cullin3 are co-located in cytoplasm (Figure 1f ). Taken together, our results show that KCTD2 is an adaptor of Cullin3 E3 ubiquitin ligase, and based on its low expression in GSCs, is a putative GSC inhibitor.
KCTD2 interacts with c-Myc and reduces its protein level. As our previous study demonstrated that Cullin3 suppresses SHH and WNT signaling through ubiquitinationdependent degradation of GLI2 and DVL2, respectively, 9 we tested whether KCTD2 was involved in GLI2 and DVL2 degradation. Western blot analysis found that KCTD2 knockdown using a KCTD2-specific short-hairpin RNA (shRNA) did not change GLI2 and DVL2 protein levels in U87MG glioma cells and immortalized astrocyte cells derived from an Ink4a/ Arf-deficient mouse (hereafter, referred to as Ink4a/Arf − / − astrocytes) (Figure 2a ). Ink4a/Arf is one of most frequently deleted tumor-suppressor genes in GBM. The expression levels of genes from the SHH (DVL1) and WNT (β-catenin, phosphorylated GSK3β, and cyclin D1) signaling pathways were not changed by KCTD2 depletion (Figure 2a) . Previous studies by another group and by us showed that Cullin3 degrades cyclin E by polyubiquitination, 9, 15 while in this study, KCTD2 depletion did not change cyclin E protein levels ( Figure 2a) . However, c-Myc, transcriptionally controlled by SHH and WNT signaling, 16, 17 was increased by KCTD2 depletion (Figure 2a ), indicating that KCTD2 regulates c-Myc protein levels independent of SHH and WNT signaling. To determine whether KCTD2 depletion changes c-Myc expression at a transcriptional level, we examined c-Myc mRNA levels using qRT-PCR. Our results showed no significant differences in c-Myc mRNA levels in KCTD2-depleted U87MG glioma cells and Ink4a/Arf − / − astrocytes ( Figure 2b ). We also examined whether Cullin3 had an effect on c-Myc protein levels. Cullin3 knockdown using a Cullin3-specific shRNA resulted in differences in c-Myc protein expression in both U87MG glioma cells and Ink4a/Arf − / − astrocytes ( Figure 2c ). Western blot analysis revealed that KCTD2 and c-Myc protein expression were inversely correlated in 7 out of 10 patients with GBM ( Figure 2d ). Thus, these results indicate that KCTD2 regulates c-Myc protein levels, but not mRNA levels.
To assess interactions between KCTD2 and c-Myc, Flagtagged KCTD2 vectors and HA-tagged c-Myc vectors were transiently transfected in HEK 293 T cells. Western blot analysis showed that KCTD2 was detected in those proteins immunoprecipitated using an anti-HA antibody. Similarly, c-Myc was detected in those proteins immunoprecipitated using an anti-Flag antibody ( Figure 3a) . Next, we examined KCTD2-dependent c-Myc polyubiquitination. The results showed that c-Myc polyubiquitination was markedly increased either by KCTD2 overexpression or by treatment with lactacystin, a proteasome inhibitor, compared with that of c-Myc overexpression alone (Figure 3b ). Furthermore, c-Myc polyubiquitination was further increased in the presence of both KCTD2 overexpression and lactacystin treatment ( Figure 3b ). We also examined the half-life of the c-Myc ). As decreased Cullin3 expression led to GSC self-renewal, we questioned whether KCTD2 was also involved in self-renewal and cancer stem cell marker expression. We first performed an in vitro limiting dilution assay to examine tumorsphereforming ability, which is a surrogate marker for self-renewal of Figure 1 Identification of KCTD2 as an adaptor of Cullin3 E3 ubiquitin ligase. (a) Overlapping clone numbers of Cullin3-binding proteins. Y2H screening was performed using Cullin3 as bait and a human fetal brain cDNA library. A total of 100 positive colonies were sequenced, of which sequence data of 98 samples were used, and 2 samples failed to sequence. (b) Relative mRNA expression levels of the KCTD2, KCTD5, KCTD6, KCTD13, KCTD17, and BTBD6 genes were analyzed using transcriptome microarray data. Relative mRNA levels in astrocytes are set to 1. Normal astrocytes (n = 4), GBMs (n = 5), and GSCs (n = 7). *Po0.05; **Po0.01; ***Po0.001. (c) Relative KCTD2 mRNA levels in 10 GSCs and 6 GBM cell lines examined using qRT-PCR. (d) Interaction between KCTD2 and Cullin3 shown using a combination of selection medium and β-gal activity was verified using one-on-one Y2H analysis. Colony formation indicates effective plasmid transformation and positive β-gal staining represents an interaction. (+) indicates a positive control (pGBKT7-p53 and pGADT7-SV40), (-) indicates a negative control (pGBKT7, which contains only the DNA binding domain) , pGADT7 (which contains only the transactivation domain), and Cullin3-KCTD2 indicates pGBKT7-hCullin3 and pACT2-KCTD2. (e) Co-immunoprecipitation analysis was performed to determine an interaction between KCTD2 and Cullin3. pIRES-Cullin3 and pcDNA-Flag-KCTD2 plasmids were transfected in HEK 293 T cells. KCTD2 proteins were immunoprecipitated (IP) using an antiFlag antibody followed by Cullin3 protein detection by western blot analysis using an anti-Cullin3 antibody. (f) Following transient transfection of pIRES-Cullin3 and pcDNA-Flag-KCTD2 plasmids in HEK 293 T cells, co-immunofluorescence analysis was performed to determine colocalization of KCTD2 (red) and Cullin3 (green). DAPI (blue) was used to stain nuclei. Scale bar represents 50 μm We also examined the expression of stem cell marker SOX2 (sex determining region Y-box2) and the glial marker GFAP (glial fibrillary acidic protein) in U87MG glioma cells and Ink4a/Arf − / − astrocytes. Fluorescenceactivated cell sorting analysis showed that KCTD2 depletion or c-Myc overexpression increased SOX2 expression and decreased GFAP expression in both cell lines (Figure 4c ). In addition, we found that these effects in KCTD2-depleted cells were restored by c-Myc knockdown (Figure 4c ). Taken together, our results show that KCTD2 depletion regulates GSC features by increasing c-Myc protein.
To validate the effects of KCTD2 knockdown tumorigenesis in vivo, we performed intracranial injection of U87MG glioma cells in nude mice and found that KCTD2 knockdown or c-Myc overexpression significantly accelerated tumor growth compared with control cells (Figures 5a and b, upper left) . We also found that increased tumor growth of KCTD2-depleted U87MG glioma cells was diminished by c-Myc knockdown (Figures 5a and b) . In addition, immunohistochemical analysis showed that the number of cells expressing GFAP were markedly decreased, whereas the number of cells expressing Nestin and SOX2 was significantly increased in tumors from KCTD2-depleted or c-Myc-overexpressed U87MG glioma cells (Figures 5a and b) . These changes in tumor growth and marker gene expression in KCTD2-depleted U87MG glioma cells were affected by c-Myc knockdown (Figures 5a  and b) . To summarize, our findings demonstrate that KCTD2 depletion promotes in vivo tumorigenesis through increases in the undifferentiated cell population by increasing c-Myc protein.
KCTD2 depletion promotes glycolysis depending on c-Myc expression level. c-Myc has an important role in aerobic glycolysis by activating glycolytic target genes, which is considered a crucial event for malignant transformation. 18 ,19 Therefore, we tested whether depletion of KCTD2 had an effect on glycolysis through c-Myc. We first measured glucose concentrations and lactate production in cell culture medium daily for 4 days. Glucose uptake was increased in KCTD2-depleted or c-Myc-overexpressed (Figure 6a ). The increased glucose uptake found in KCTD2-depleted U87MG glioma cells was significantly reduced by c-Myc knockdown (Figure 6a) . Similarly, lactate accumulation was markedly increased in KCTD2-depleted or c-Myc-overexpressed U87MG glioma cells (Figure 6b ). The increased lactate accumulation found in KCTD2-depleted U87MG glioma cells was significantly decreased by c-Myc knockdown (Figure 6b ). Furthermore, qRT-PCR analysis showed that KCTD2 depletion or c-Myc overexpression led to increased expression in genes involved in glucose uptake (glucose transporter 1; GLUT1) and glycolysis (ASC amino-acid transporter 2 (ASCT2), hexokinase 2 (HK2), enolase 1 (ENO1), lactate dehydrogenase A (LDHA), lactate dehydrogenase B (LDHB), phosphoinositidedependent kinase 1 (PDK1), and monocarboxylate transporter 1 (MCT1)), all which are well-known target genes of c-Myc (Figure 6c ). These changes in KCTD2-depleted cells were markedly restored by c-Myc knockdown (Figure 6c ). Altogether, these results indicate that KCTD2 depletion activates aerobic glycolysis through changes in glycolytic metabolic gene expression by increasing c-Myc protein.
KCTD2 and c-Myc gene signatures correlate with clinical outcomes of patients with malignant glioma. To evaluate the clinical relevance of KCTD2 expression, we interrogated the Repository of Molecular Brain Neoplasia Data (REMBRANDT) data set. 20 KCTD2 mRNA levels were decreased in astrocytoma, oligodendrocytoma, and GBM compared with non-tumors (Figure 7a ). GBM was recently classified into four subtypes by gene expression profiles: neural, proneural, classical, and mesenchymal. 21 Among these subtypes, the proneural and neural subtypes are similar to a low-grade glioma, whereas the classical and mesenchymal subtypes are more similar to a higher grade glioma. 22 The classical and mesenchymal subtypes are known to be more aggressive than neural and proneural subtypes. 21 KCTD2 mRNA was highly expressed in the neural subtype compared with the other subtypes, whereas its expression was lowest in the classical subtype (Figure 7b ). To further delineate the significance of KCTD2-mediated regulation of c-Myc protein, we tested for correlations between KCTD2 mRNA levels and c-Myc protein levels in patients with malignant glioma. As the REMBRANDT data set does not provide protein expression levels, c-Myc protein levels were substituted with a c-Myc gene signature (a combination of c-Myc's downstream target genes). KCTD2 mRNA expression inversely correlated with the c-Myc gene signature but not with c-Myc mRNA levels (Figures 7c and d) . There was no correlation between c-Myc mRNA levels and the c-Myc gene signature (Figure 7e ). Among the Cullin3-binding adaptors identified using the Y2H assay (Figure 1a) , only KCTD2 expression was negatively correlated with the c-Myc gene signature (data not shown). Furthermore, the c-Myc gene signature, not c-Myc mRNA levels, was strongly correlated with poor survival of patients with malignant glioma (Figures 7f and g ). Patients with malignant glioma with (Figure 7h) . Thus, our bioinformatics analysis showed that c-Myc protein expression and its transcriptional activity, rather than c-Myc mRNA levels, are significant indicators for survival prognosis of patients with malignant glioma. Taken together, the clinical significance of KCTD2 expression levels that are significantly lower in patients with aggressive glioma and are correlated with reduced survival may be attributed to increased c-Myc protein and transcriptional activity.
Discussion
Recent studies have found a functional role of Cullin3 E3 ubiquitin ligase in different human malignancies. Genetic deregulation of the Cullin3 complex leads to activation of NFκB signaling in patients with lung cancer, 23 and reduced Cullin3 expression was associated with human liver cancer progression. 24 The decreased Cullin3 by inhibitor of differentiation 1 induces stem cell properties in GBM by activating intracellular SHH and WNT through stabilization of GLI2 and DVL2, respectively. 9 Thus, Cullin3 is a key regulator of cancer progression. However, the underlying mechanisms and substrate recognition specificity of Cullin3 are not fully understood. Therefore, in this study, we carried out Y2H screening to identify Cullin3-interacting BTB domain proteins.
Among the binding partners with Cullin3 in Figure 1a , it has been found that KCTD6, KCTD13, and BTB domaincontaining 6 (BTBD6) are well-characterized adaptors for the Cullin3 complex. For example, KCTD6-Cullin3 complex promoted the degradation of small ankyrin-1 in the cardiomyocytes as well as HDAC1 protein in the pediatric malignant primary brain tumor. 25, 26 Moreover, KCTD13 and BTBD6 downregulated the protein stability of RhoA and Plzf via the interaction with Cullin3, respectively. 27, 28 In contrast, we found no evidence that Cullin3 interacts with KCTD2 protein as a BTB domain adaptor. According to expression pattern of KCTD2 that is low in GSCs compared with glioma cells, we depleted KCTD2 expression in glioma cells and immortalized astrocyte, and c-Myc is highly expressed in embryonic stem cells and can generate induced pluripotent stem cells. 29 A recent study found that c-Myc is required for diverse features of GSCs. 12 c-Myc is dysregulated by c-Myc gene amplification in malignant gliomas and its c-Myc nuclear expression levels are associated with increased tumor aggressiveness. 30 Similarly, our bioinformatics analysis using the REMBRANDT data set revealed that c-Myc transcription activity, as determined by the c-Myc gene signature, but not c-Myc mRNA levels, is correlated with worse survival of patients with malignant gliomas. These results suggest that regulation of c-Myc protein levels rather than its mRNA levels is more critical for its function in malignant glioma pathogenesis. Therefore, increased c-Myc protein stability by decreased KCTD2 is a critical mechanism to regulate its transcriptional activity and effects on aerobic glycolysis, self-renewal, and tumor growth.
Several studies have demonstrated that c-Myc protein stability is regulated by phosphorylation. The RAF-MEK-ERK pathway stabilizes the c-Myc protein by phosphorylation at serine 62, whereas protein phosphatase 2 promotes ubiquitination-mediated degradation of c-Myc by dephosphorylation at serine 62. 31 A recent study demonstrated that FBW7 ubiquitin ligase has an important role in tumor suppression. One of the molecular mechanisms underlying the tumor suppression function of FBW7 ligase is degradation of c-Myc protein. FBW7 ligase regulates c-Myc protein degradation by recognizing phosphorylation of c-Myc at threonine 58. However, mutation of c-Myc at threonine 58 was frequently detected in several cancers. 31 Although cancers containing this mutation are not affected by this c-Myc inactivation mechanism, which results in the accumulation of c-Myc protein and accelerated tumor progression. c-Myc protein is also increased in several tumors that have mutations in FBW7. 32 Therefore, understanding other mechanisms governing c-Myc inactivation is essential to establishing a therapeutic modality targeting c-Myc in various human malignancies. In the present report, we showed that the BTB domain-containing KCTD2 adaptor interacts with Cullin3 ubiquitin ligase and the c-Myc protein, and induces c-Myc protein degradation. KCTD2 expression is lower in GSCs compared with glioma cells, and depletion of KCTD2 leads to tumorigenic properties by increasing c-Myc protein. Therefore, the molecular mechanism governing c-Myc activity by the Cullin3-KCTD2 complex is important for c-Myc stability in malignant gliomas, and may provide an alternative strategy for targeting the c-Myc protein (Figure 7i ).
Materials and Methods Y2H library screening. Y2H screening was performed as described previously. 33 Briefly, the bait vector pGBKT7-Cullin3 was transformed in yeast strain Saccaromyes cerevisiae AH109 using the LiAc/polyethylene glycol method and then used to screen a pretransformed MATCHMAKER human fetal brain library (Clontech, Palo Alto, CA, USA), cloned in pACT2, by mating with the yeast strain Y187.
REMBRANDT data analysis. The REMBRANDT data set was used to identify correlations between clinical characteristics, gene expression, and survival of KCTD2 and c-Myc in glioma specimens. First, clinical 'information-lacking tumor samples' (n = 199, including unknown, mixed, survival information-lacked) were excluded from the REMBRANDT data set (n = 534), with the remaining samples named 'tumor type-recorded glioma'. Second, tumor samples that did not have tumor grade information (n = 21) were excluded from the tumor type-recorded glioma set (n = 335), and were named 'second group'. Patient samples in the second group (n = 314) were used to analyze KCTD2 gene expression in FACS analysis. Cells were dissociated into single cells using Trypsin-EDTA (Sigma-Aldrich), washed, and suspended in phosphate-buffered saline (PBS). Cells were fixed using 4% paraformaldehyde and subsequently permeabilized using 0.1% BSA, 1% serum, and 1% Triton. For analysis of target protein expression, cells were stained with the respective primary antibody such as anti-Nestin (Sigma-Aldrich), anti-SOX2 (R&D Systems), anti-CD133 (Miltenyi Biotec, Bergisch Gladbach, Germany), and anti-GFAP (MP Biomedicals, Santa Ana, CA, USA), followed by incubation with a biotin-conjugated secondary antibody and PE-conjugated avidin (BD Pharmingen, San Diego, CA, USA). Fluorescence intensities were measured using FACS Verse (BD Pharmingen, San Jose, CA, USA).
In vitro limiting dilution sphere formation assay. For the in vitro limiting dilution assay, a decreasing number of cells (500, 250, 100, 50, and 10) were manually seeded per well in 96-well plates containing DMEM/F12 with B27, EGF, and bFGF (n = 18). Neurospheres larger than 10 μm in diameter were counted by light microscopy after 14 days. Stem cell frequency was calculated using ELDA software available at http:bioinf.wehi.edu.au/software/elda. 34 Intracranial injection assay. U87MG glioma cells were harvested by trypsinization, washed with PBS, and cell viability was determined by Trypan blue exclusion. Single-cell suspensions with 490% viability were used for in vivo studies. Cells (5 × 10 4 in 3 μl of PBS) were stereotactically injected into the left striatum of 6-week-old BALB/c nu/nu mice (coordinates relative to the bregma: anterior-posterior +2 mm, medial-lateral +2 mm, and dorsal-ventral -3 mm). Mice whose body weight had decreased by 425% were considered to have an intracranial tumor. Mice harboring tumors were perfused with PBS and 4% paraformaldehyde. Intracranial tumor tissues were embedded in paraffin, sectioned (4 μm thickness) and stained with hematoxylin and eosin (H&E) at histologically similar positions. Intracranial tumor size was measured using MetaMorph software. The total brain area was divided by H&E-stained tumor regions. All animal experiments were approved by the animal care committee of Korea University (Seoul, Republic of Korea), and were performed in accordance with government and institutional guidelines and regulations.
Statistical analysis. Data were analyzed using a two-tailed Student's t-test. P values o0.05 (indicated by * , #, @ ), o0.01 (indicated by ** , ##, @@ ) and o0.001 (indicated by *** , ###, @@@ ) were considered statistically significant. Data were presented as the mean ± S.D.
